SEARCH

SEARCH BY CITATION

References

  • 1
    Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 18601861.
  • 2
    Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 16301636.
  • 3
    A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987994.
  • 4
    AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
  • 5
    Gall E, Mallory T. Malignant lymphoma. A clinicopathologic survey of 618 cases. Am J Pathol 1942; 18: 381.
  • 6
    Hicks EB, Rappaport H, Winter WJ. Follicular lymphoma; a re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 1956; 9: 792821.
  • 7
    Lukes RJ, Collins RD. Immunologic characterization of human malignant lymphomas. Cancer 1974; 34 (4 Suppl): 14881503.
  • 8
    Lennert K, Stein H. Malignant Lymphomas Other than Hodgkin's Disease: Histology, Cytology, Ultrastructure, Immunology. New York: Springer-Verlag; 1978.
  • 9
    Lennert K, Stein H, Kaiserling E. Cytological and functional criteria for the classification of malignant lymphomata. Br J Cancer 1975; 31(Suppl 2)): 2943.
  • 10
    National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 21122135.
  • 11
    Rimokh R, Berger F, Delsol G, et al. Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias. Blood 1993; 81: 30633067.
  • 12
    Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848858.
  • 13
    Kaneko Y, Frizzera G, Edamura S, et al. A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis. Blood 1989; 73: 806813.
  • 14
    Rimokh R, Magaud JP, Berger F, et al. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (‘Ki-1 lymphoma’). Br J Haematol 1989; 71: 3136.
  • 15
    Bitter MA, Franklin WA, Larson RA, et al. Morphology in Ki-1(CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35). Am J Surg Pathol 1990; 14: 305316.
  • 16
    Mason DY, Bastard C, Rimokh R, et al. CD30-positive large cell lymphomas (‘Ki-1 lymphoma’) are associated with a chromosomal translocation involving 5q35 [see comments]. Br J Haematol 1990; 74: 161168.
  • 17
    Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983; 52: 14101416.
  • 18
    Isaacson P, Wright DH. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer 1984; 53: 25152524.
  • 19
    Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 13611392.
  • 20
    The non-Hodgkin's Lymphoma classification project: a clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 39093918.
  • 21
    Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, in Jaffe E, Harris N, Stein H, Vardiman J (eds). World Health Organization Classification of Tumors. Lyon: IARC Press; 2001.
  • 22
    Hehn ST, Grogan TM, Miller TP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol 2004; 22: 30463052.
  • 23
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649655.
  • 24
    Longo DL, DeVita VT, Jr., Duffey, PL, et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 1991; 9: 2538.
  • 25
    Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596602.
  • 26
    Shipp MA, Yeap BY, Harrington DP, et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 1990; 8: 8493.
  • 27
    Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 10021006.
  • 28
    Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 12581265.
  • 29
    Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 19371947.
  • 30
    Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 6874.